Hong Kong / HKGI CSO on the Hong Kong Genome Project
Dr Brian CHUNG Hon-Yin, Chief Scientific Officer at the Hong Kong Genome Institute (HKGI) and Clinical Associate Professor at the University of Hong Kong (HKU) discusses the creation of the…
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – Oncology, Cardiovascular & Metabolic Disease and Respiratory. We are also selectively active in the areas of autoimmunity, neuroscience and infection. Its presence in Hong Kong – in the name of AstraZeneca Hong Kong – can be traced back to 1999 when AstraZeneca was formed following a merger of Astra AB of Sweden and Zeneca Group PLC of the UK. Both companies were established in Hong Kong in the 1970s.
AstraZeneca Hong Kong oversees both the Hong Kong and Macau markets and attaches a strong importance to them. Since our establishment, we have been focusing on identifying and bringing in the latest medical solutions as well as seeking ongoing business development. Over the years, we have been continually expanding our business in order to meet the growing demand of the markets.
Contact
Address: Unit 1-3, 11/F, 18 King Wah Road, North Point
Tel: +(852) 2420 7388
Website: https://www.astrazeneca.com/country-sites/hong-kong.html
Dr Brian CHUNG Hon-Yin, Chief Scientific Officer at the Hong Kong Genome Institute (HKGI) and Clinical Associate Professor at the University of Hong Kong (HKU) discusses the creation of the…
Leveraging his 24-year career in Big Pharma, Howard Lin recently moved to set up healthcare and life science consultancy CL Consultancy in Hong Kong. Lin examines the opportunities and challenges…
2023 got off to a good start for Boehringer Ingelheim’s human pharma division. Not only has the year begun with substantial sales growth thanks to the German firm’s diabetes and…
Looking ahead to the Hong Kong International Biotechnology Convention (BIOHK2023) taking place between 13-16 September 2023 at the Hong Kong Convention and Exhibition Centre, three of the event’s leading lights…
Henry Yau is managing director of the Hong Kong University (HKU) Clinical Trials Centre in Hong Kong and CEO of the Centre’s mainland China arm. Yau explains how the clinical…
MSD’s managing director for Hong Kong and Macau, Vincent Tong, came to lead the affiliate during the COVID-19 pandemic. He outlines the challenges and opportunities of a challenging time, discusses…
Executive director & chief strategy officer at HKEX-listed RNA therapeutics biotech Sirnaomics, Dr Dai Xiaochang is no stranger to Hong Kong and mainland China’s pharma and biotech ecosystem, having held…
Paul Tam, who serves as chair professor & VP at Macau University of Science and Technology as well as emeritus professor and honorary clinical professor of surgery at the University…
Based at Gilead Sciences’ Hong Kong hub, as VP & GM of Asia, Turkey, and the Middle East, American Dustin Haines oversees a vast region that includes the “Asia 5”…
Malaysian national Jonathan Chin culminated his 20+-year career at Boehringer Ingelheim and became GM of the firm’s Hong Kong and Macau affiliate in 2022. He explains his career path through…
Managing partner Nisa Leung co-founded three healthcare companies before starting the venture capital firm Qiming Venture Partners, a pioneer in China that has backed over 530 fast-growth companies, including Xiaomi,…
Serial entrepreneur Dr. Gina Jiang built a number of successful medtech startups in Silicon Valley before joining the Hong Kong Institute of Biotechnology (HKIB) as its managing director. She discusses…
See our Cookie Privacy Policy Here